Oppenheimer & Co. Inc. Sells 4,552 Shares of iShares Biotechnology ETF $IBB

Oppenheimer & Co. Inc. reduced its stake in iShares Biotechnology ETF (NASDAQ:IBB) by 14.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 26,267 shares of the financial services provider’s stock after selling 4,552 shares during the period. Oppenheimer & Co. Inc.’s holdings in iShares Biotechnology ETF were worth $3,792,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. SPC Financial Inc. boosted its stake in iShares Biotechnology ETF by 21.9% in the 3rd quarter. SPC Financial Inc. now owns 3,890 shares of the financial services provider’s stock worth $562,000 after purchasing an additional 700 shares in the last quarter. Bond & Devick Financial Network Inc. bought a new stake in iShares Biotechnology ETF during the 3rd quarter valued at about $203,000. Flagship Harbor Advisors LLC purchased a new position in iShares Biotechnology ETF in the third quarter worth about $280,000. SBI Securities Co. Ltd. lifted its stake in shares of iShares Biotechnology ETF by 9.4% in the third quarter. SBI Securities Co. Ltd. now owns 2,120 shares of the financial services provider’s stock worth $306,000 after buying an additional 182 shares in the last quarter. Finally, Finer Wealth Management Inc. lifted its stake in shares of iShares Biotechnology ETF by 2.7% in the third quarter. Finer Wealth Management Inc. now owns 9,380 shares of the financial services provider’s stock worth $1,354,000 after buying an additional 245 shares in the last quarter. 62.45% of the stock is currently owned by institutional investors.

iShares Biotechnology ETF Trading Up 0.4%

NASDAQ:IBB opened at $172.70 on Thursday. The company’s 50 day moving average price is $171.68 and its 200-day moving average price is $156.88. iShares Biotechnology ETF has a 52 week low of $107.43 and a 52 week high of $179.64.

iShares Biotechnology ETF Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, December 19th. Shareholders of record on Tuesday, December 16th were issued a $0.1831 dividend. This represents a $0.73 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date of this dividend was Tuesday, December 16th. This is a positive change from iShares Biotechnology ETF’s previous quarterly dividend of $0.08.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.